No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Syndax Pharma Publishes Data From Pivotal Phase 2 Portion Of AUGMENT-101 Trial Of Revumenib In Patients With R/R MNPM1 Acute Myeloid Leukemia In Blood
BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Raises Target Price to $26
Barclays Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $19
Scotiabank Maintains Syndax Pharmaceuticals(SNDX.US) With Hold Rating, Raises Target Price to $17
12 Health Care Stocks Moving In Tuesday's Intraday Session
Syndax Pharmaceuticals Is Maintained at Sector Perform by Scotiabank